بدائل البحث:
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
sizes decrease » scores decreased (توسيع البحث), rivers decreased (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
sizes decrease » scores decreased (توسيع البحث), rivers decreased (توسيع البحث)
-
1
Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size.
منشور في 2025"…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …"
-
2
Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization
منشور في 2025"…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. …"
-
3
-
4
-
5
Mean scores, standard deviations, and significance on key measures and subscales by gender group.
منشور في 2025الموضوعات: -
6
-
7
-
8
-
9
-
10
-
11
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
12
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
13
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
14
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
منشور في 2025"…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …"
-
15
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
16
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
17
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: -
18
B2 decreases glycolytic intermediates in cells.
منشور في 2025"…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …"
-
19
-
20